Trial Profile
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 26 Apr 2022 Status changed from active, no longer recruiting to completed.
- 17 Dec 2021 Planned End Date changed from 1 Jul 2022 to 1 Aug 2022.
- 17 Dec 2021 Planned primary completion date changed from 1 Jul 2022 to 1 Aug 2022.